Company News: Page (1) of 1 - 05/16/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Forty Seven, Inc. to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

-- Oral Presentations Include Preliminary Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (r/r NHL) and Data from Phase 1 Phar... (May 16, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business Issues,Presentation, Inc.,Science,Medical,Cancer,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved